中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
2,6-二硝基萘 | 2,6-dinitronaphthalene | 24824-26-8 | C10H6N2O4 | 218.169 |
—— | 2-nitro-6-chloronaphthalene | 56961-37-6 | C10H6ClNO2 | 207.616 |
2-羟基-6-硝基萘 | 6-Nitro-[2]naphthol | 38397-07-8 | C10H7NO3 | 189.17 |
2-氟-6-硝基萘 | 2-fluoro-6-nitronaphthalene | 13790-81-3 | C10H6FNO2 | 191.162 |
—— | 2-bromo-6-nitronaphthalene | 67878-77-7 | C10H6BrNO2 | 252.067 |
1-溴-6-硝基萘 | 1-Brom-6-nitro-naphthalin | 67878-75-5 | C10H6BrNO2 | 252.067 |
—— | 2-methoxy-6-nitronaphthalene | 4900-67-8 | C11H9NO3 | 203.197 |
6-硝基-[2]萘甲酸 | 6-nitro-[2]naphthoic acid | 5783-91-5 | C11H7NO4 | 217.181 |
—— | 2-(6-nitro-2-naphthyl)hydrazinecarboxylate, ethyl ester | 220032-04-2 | C13H13N3O4 | 275.264 |
—— | 1,3,5,7-tetranitro-naphthalene | 60619-96-7 | C10H4N4O8 | 308.164 |
2,6-萘二胺 | naphthalene-2,6-diamine | 2243-67-6 | C10H10N2 | 158.203 |
Neurocognitive impairment is a frequent complication of HIV infection and heralds a poor survival prognosis. With the availability of highly active antiretroviral therapy (HAART), survival times for HIV-infected patients have markedly increased although the effects of HAART on the prevalence of neurocognitive impairment remain uncertain.
To determine the relationship between self-reported neurocognitive symptoms and neuropsychological (NP) performance together with the impact of HAART among HIV-infected patients.
A cross-sectional study was performed in which patients without previously documented neurocognitive impairment attending an HIV community clinic were questioned about neurocognitive symptoms and a NP test battery was administered.
Of the eighty-three patients examined, neurocognitive symptoms were reported by 34% of patients and were associated with a shorter duration of HAART and higher viral loads. Patients reporting neurocognitive symptoms were also more likely to exhibit impaired NP performance (p<0.005) with NP impairment being detected in 46% of all patients examined (12% with HIV-associated dementia). Neuropsychological impairment was directly correlated with age (p<0.001), plasma viral load (p<0.005) and inversely correlated with the number of prescribed antiretroviral drugs (p<0.01).
These results suggest that neurocognitive symptoms are predictive of impaired NP performance and that NP impairment remains a frequent finding among older patients with higher viral loads. An increased number of antiretroviral drugs may be neuroprotective.